Effects of chronic cocaine self-administration on norepinephrine transporters in the nonhuman primate brain.
BACKGROUND
While cocaine blocks dopamine and serotonin transporters, considerably less emphasis has been placed on its effects following blockade of the norepinephrine transporter (NET). To date, no studies have made a systematic investigation of the effects of chronic cocaine on primate NET density.


OBJECTIVE
We previously reported increases in NET density in portions of the monkey bed nucleus of stria terminalis after 100 days of cocaine self-administration. In the present study we extend these findings and assess the changes in [3H]nisoxetine binding in additional brain regions of rhesus monkeys chronically self-administrating cocaine.


RESULTS
[3H]Nisoxetine binding sites in the A1 noradrenergic cell group were significantly higher after 5 days of cocaine exposure. One hundred days of self-administration also induced a higher density of NET binding within the A1 cell group; however, in addition, the effects extended to the nucleus prepositus, as well as forebrain regions such as hypothalamic nuclei, basolateral amygdala, parasubiculum, and entorhinal cortex.


CONCLUSIONS
These data demonstrate that cocaine self-administration alters the noradrenergic system of nonhuman primates. Although cocaine affected NET binding sites in the forebrain projections of both the ventral (VNAB) and dorsal (DNAB) noradrenergic bundles, the alteration in the A1 cell group at the early time-point suggests that the VNAB appears to be more sensitive than the DNAB to the effects of cocaine. Given the role of norepinephrine in arousal and attention, as well as mediating responses to stress, long-term exposure to cocaine is likely to result in significant changes in the way in which information is perceived and processed by the central nervous system of long-term cocaine users.
Beveridge
Thomas J R
TJ
Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Smith
Hilary R
HR
Nader
Michael A
MA
Porrino
Linda J
LJ
D000818:Animals; D001345:Autoradiography / Q000379:methods; D001522:Behavior, Animal; D001921:Brain / Q000033:anatomy & histology / Q000187:drug effects* / Q000378:metabolism; D001931:Brain Mapping; D002247:Carbon Isotopes / Q000493:pharmacokinetics; D003042:Cocaine / Q000008:administration & dosage*; D003847:Deoxyglucose / Q000493:pharmacokinetics; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005473:Fluoxetine / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D008253:Macaca mulatta; D008297:Male; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000378:metabolism*; D011485:Protein Binding / Q000187:drug effects; D012646:Self Administration; D014316:Tritium / Q000493:pharmacokinetics
D002247:Carbon Isotopes; D018765:Dopamine Uptake Inhibitors; D050484:Norepinephrine Plasma Membrane Transport Proteins; D005473:Fluoxetine; D014316:Tritium; C011386:nisoxetine; D003847:Deoxyglucose; D003042:Cocaine
Brain Res. 1993 Nov 19;628(1-2):17-25
8313144
J Pharmacol Exp Ther. 1999 Sep;290(3):1347-55
10454513
J Neurosci. 1999 Oct 15;19(20):RC35
10516337
Life Sci. 1988;43(4):309-15
2969443
Neuroscience. 1988 Oct;27(1):1-39
3059226
Brain Res. 1994 Feb 28;638(1-2):182-8
7515319
Nature. 2000 Jan 27;403(6768):430-4
10667795
Brain Res. 1990 Jun 4;518(1-2):227-43
1697208
J Pharmacol Exp Ther. 1996 Apr;277(1):225-34
8613924
J Comp Neurol. 1993 Jun 1;332(1):105-22
7685779
Nature. 1997 Apr 24;386(6627):827-30
9126740
J Pharmacol Exp Ther. 1995 Mar;272(3):1176-86
7891330
J Pharmacol Exp Ther. 1991 Nov;259(2):495-500
1658300
J Pharmacol Exp Ther. 1992 Jan;260(1):427-36
1731049
Neuropsychopharmacology. 2002 Jul;27(1):35-46
12062905
J Pharmacol Exp Ther. 1994 Sep;270(3):1134-8
7932162
Brain Res. 1996 Oct 14;736(1-2):287-96
8930335
J Neurosci. 1999 Jun 15;19(12):5119-23
10366644
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11642-7
10500230
Neuroscience. 1998 Jun;84(4):967-96
9578390
Nature. 1996 Feb 15;379(6566):606-12
8628395
Neurosci Biobehav Rev. 2004 Jan;27(8):813-20
15019430
Neurosci Lett. 2004 Nov 11;370(2-3):201-5
15488323
Brain Res Mol Brain Res. 2000 Nov 10;83(1-2):107-20
11072100
J Neurosci. 2002 Jul 1;22(13):5713-8
12097523
J Pharmacol Exp Ther. 1992 May;261(2):476-83
1578363
Ann N Y Acad Sci. 1999 Jun 29;877:486-98
10415666
Neuropsychopharmacology. 2000 Aug;23(2):138-50
10882840
Curr Opin Neurobiol. 2001 Apr;11(2):250-7
11301247
J Comp Neurol. 1991 Jul 22;309(4):445-85
1918444
Mol Cell Neurosci. 1994 Apr;5(2):189-95
8032687
J Neurosci. 2002 Sep 1;22(17):7687-94
12196592
Life Sci. 1990;46(9):635-45
2308472
J Pharmacol Exp Ther. 1995 Oct;275(1):53-62
7562595
J Neurosci. 2001 Apr 15;21(8):2799-807
11306632
Neuropsychopharmacology. 2004 Apr;29(4):686-93
14872205
Brain Res. 1995 Feb 20;672(1-2):289-97
7749750
J Comp Neurol. 1986 Sep 22;251(4):451-73
2431009
Psychopharmacology (Berl). 2001 Dec;158(4):360-5
11797056
Drug Alcohol Depend. 2001 Jun 1;63(1):69-78
11297832
J Pharmacol Exp Ther. 1998 Mar;284(3):1015-25
9495862
J Pharmacol Exp Ther. 2000 Dec;295(3):951-9
11082428
Brain Res. 1989 Dec 25;505(1):7-11
2611679
Brain Res Mol Brain Res. 1997 Oct 3;49(1-2):95-102
9387868
Drug Alcohol Depend. 1991 Jan;27(1):51-61
1709403
Psychopharmacology (Berl). 1992;106(4):459-62
1579620
Psychoneuroendocrinology. 2002 Jan-Feb;27(1-2):13-33
11750768
Psychopharmacology (Berl). 1997 Jun;131(3):307-12
9203242
Eur J Pharmacol. 1990 Sep 4;186(1):1-8
2282931
Arch Gen Psychiatry. 1994 Sep;51(9):713-9
8080348
J Neurochem. 2002 Apr;81(2):292-300
12064476
J Neurosci. 2003 Jan 1;23(1):12-6
12514195
Can J Psychol. 1977 Dec;31(4):195-203
608135
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5300-5
11320258